Veru Reports Third Quarter Fiscal 2022 Financial Results; Progresses Sabizabulin Treatment for COVID-19 Towards Regulatory Decisions in Key Territories

11.08.2022 - -Sabizabulin for COVID-19 Emergency Use Authorization Application Submitted to U.S. FDA in June 2022- -The UK’s Medicines and Healthcare Products Regulatory Agency Informed the Company that its Sabizabulin Marketing Authorization Application Will ...

Related Keywords

Miami ,Florida ,United States ,United Kingdom ,Massachusetts ,Mitchell Steiner ,Samuel Fisch ,Sexual Health Division ,Ar Prostate Cancer Program ,European Medicines Agency Emergency Task ,Nasdaq ,Company To Host Investor Conference Call ,Breast Cancer Program ,European Union ,Veru Inc ,Massachusetts Medical Society ,Goodrx Inc ,Patients For Emergency Use In European Union ,Data Monitoring Committee ,Company Form ,Exchange Commission ,Corporate Communications ,Healthcare Products Regulatory Agency ,European Medicines Agency ,Emergency Task Force Initiated Review ,Sabizabulin Treatment ,Emergency Use ,New England Journal ,Medicine Evidence Published Phase ,Trial Results Demonstrating ,High Risk Hospitalized ,Company Prepares ,Emergency Authorizations Are ,Host Investor Conference Call Today ,Acute Respiratory Distress ,Quarter Financial Summary ,Date Financial Summary ,Chief Executive Officer ,Emergency Use Authorization ,Emergency Task ,Pipeline Highlights ,Disease Franchise ,Positive Phase ,Hospitalized Moderate ,High Risk ,Independent Data ,Monitoring Committee ,Emergency Task Force ,Line Treatment ,Breast Cancerwith ,Combination Therapy ,Breast Cancer ,Novel Oral Cytoskeleton Disruptor Agent ,Metastatic Castration ,Antagonist Peptide ,Month Subcutaneous Depot Formulation ,Androgen Deprivation Therapy ,Advanced Prostate Cancer ,Benign Prostatic Hyperplasia ,Private Securities Litigation Reform Act ,Fast Track ,Consolidated Statements ,Media Contact ,Investor Relations ,